Vitaly Balan serves as the Head of Molecular Engineering and Principal Investigator at the Champalimaud Foundation, where he leads pioneering research aimed at transforming the landscape of cancer and age-related disease therapies. With a robust background in genomics and biochemistry, Vitaly is at the forefront...
Vitaly Balan serves as the Head of Molecular Engineering and Principal Investigator at the Champalimaud Foundation, where he leads pioneering research aimed at transforming the landscape of cancer and age-related disease therapies. With a robust background in genomics and biochemistry, Vitaly is at the forefront of developing innovative CAR-T platforms specifically designed to target solid tumors, a significant challenge in current oncology treatments. His expertise in Next Generation Sequencing (NGS) data analysis and transcriptome profiling allows him to identify novel biomarkers and therapeutic targets, enhancing the precision of personalized medicine.
Under his leadership, the Molecular Engineering platform at Champalimaud has made significant strides in the design and production of advanced molecular tools. Vitaly has successfully overseen multiple key projects that involve pre-clinical testing of these tools, ensuring they meet the rigorous standards necessary for potential clinical application. His commitment to functional genomics and cancer biology drives the research team to explore new avenues for cellular and molecular therapeutics, ultimately aiming to improve patient outcomes.
Vitaly’s proficiency in programming languages such as Python, alongside his hands-on skills in tissue culture, protein purification, and ELISA, enables him to integrate computational and experimental approaches effectively. His work not only contributes to the scientific community’s understanding of complex biological systems but also positions the Champalimaud Foundation as a leader in the development of next-generation therapies. Through his innovative research and collaborative leadership, Vitaly Balan is making significant contributions to the fight against cancer and age-related diseases, paving the way for breakthroughs that could redefine treatment paradigms.
